Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Astellas and Hovon Confirm Phase 3 Study Did not Meet its Primary Endpoint of Overall Survival in Patients with Newly Diagnosed FLT3m+ AML
Presentation Material for Sustainability Meeting (FY2025)
Astellas Reaches Settlement Agreements with Lupin and Zydus in Myrbetriq Patent Litigation
Notice Regarding Revision of Financial Forecasts for FY2025
Presentation Material for information Meeting (Q3 YTD/FY2025)
Supplementary Documents (Q3 YTD/FY2025)
Financial Results (Q3 YTD/FY2025)
Astellas Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 39%, Highest in Seven Terms
PADCEV Plus Keytruda Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Astellas Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 38%
Notice Regarding Revision of Financial Forecasts for FY2025
Presentation Material for information Meeting (Q2 YTD/FY2025)
Supplementary Documents (Q2 YTD/FY2025)
Financial Results (Q2 YTD/FY2025)
Astellas Confirms Phase 2 GLEAM Trial Did Not Meet Primary Endpoint of Overall Survival in Patients with Metastatic Pancreatic Cancer
Astellas Receives Conditional Approval for IZERVAY in Japan
PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
Presentation Material for Information Meeting (Q1 YTD/FY2025)
[Summary]Financial Results (Q1 YTD/FY2025)
Astellas Pharma, Apr-Jun (1Q) Net Income Increases by 82%